NOS2 and melanoma: We propose that the NO/Ets-1 signaling axis first described here may promote disease progression in other tumors that overexpress NOS2, such as glioma and melanoma [2,57], and tumors with impaired SNO metabolism, such as lung and hepatocellular carcinoma [55,58].